Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
University of Wisconsin, Madison
Summary
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 18 years or older * Able and willing to provide informed consent * Known diagnosis of prostate cancer * Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET * Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases. * Willing and able to undergo PET/MRI as part of this research Exclusion Criteria: * Unable or unwilling to provide informed consent * Contraindication(s) to or inability to undergo PET/MRI * Participants for whom PET/MRI will delay timely delivery of treatment * Participants requirin…
Interventions
- RadiationFAPI
5 +/- 2 mCi of Ga-FAPI-46
- ProcedurePositron Emission Tomography (PET)
Undergo PET scan
- ProcedureMagnetic Resonance Imaging
Undergo MRI scan
Location
- University of WisconsinMadison, Wisconsin